

C (cont.)

- (b) amino acids 2 to 381 of SEQ ID NO:2;
- (c) amino acids 25 to 381 of SEQ ID NO:2; and
- (d) a polypeptide fragment of SEQ ID NO:2, wherein said fragment stimulates cellular proliferation.

Sub D

34. (Once Amended) An isolated polypeptide comprising a first amino acid sequence that is at least 95% identical to a second amino acid sequence selected from the group consisting of:

- (a) amino acids 1 to 381 of SEQ ID NO:2;
- (b) amino acids 2 to 381 of SEQ ID NO:2;
- (c) amino acids 25 to 381 of SEQ ID NO:2; and
- (d) a polypeptide fragment of SEQ ID NO:2;

wherein said polypeptide stimulates cellular proliferation.

20. 59. (Once Amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of the full-length polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75804;
- (b) the amino acid sequence of the full-length polypeptide, lacking the N-terminal methionine, encoded by the human cDNA contained in ATCC Deposit Number 75804;
- (c) the amino acid sequence of the mature polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75804; and
- (d) a polypeptide fragment of the polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75804, wherein said fragment stimulates cellular proliferation.

Sub 13

72. (Once Amended) An isolated polypeptide comprising a first amino acid sequence that is at least 95% identical to a second amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of the full-length polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75804;

*S 11B
D 13
P 14
10/04/02*

- (b) the amino acid sequence of the full-length polypeptide, lacking the N-terminal methionine, encoded by the human cDNA contained in ATCC Deposit Number 75804;
- (c) the amino acid sequence of the mature polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75804; and
- (d) a polypeptide fragment of the polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75804;

wherein said polypeptide stimulates cellular proliferation.

Remarks

Claims 1, 30, 31, 32, 37, 38, 41, 42, 45, 46, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 68, 69, 70, 71, 75, 76, 79, 80, 83, 84, 87, 88, 89, 90, 91, 92, 93, 94, 95, and 96 will be canceled, claims 21, 34, 59, and 72 will be amended, and claims 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 35, 36, 39, 40, 43, 44, 47, 48, 59, 60, 61, 62, 63, 64, 65, 66, 67, 72, 73, 74, 77, 78, 81, 82, 85, and 86 will be pending upon entry of this amendment. Applicants respectfully request reconsideration of the rejections and objections in view of the following remarks.

Election/Restriction

Although Applicants respectfully disagree with the Examiner's maintenance of the restriction requirement, Applicant's acknowledge the finality of the restriction requirement.

Applicants retain the right to petition from the restriction requirement under 37 C.F.R. § 1.144.

Claim Objections

Applicants appreciate the Examiner's renumbering of the claims, and acknowledge the renumbering of pending claims 23-96.

Rejections of the Claims Under 35 U.S.C. § 112, Second Paragraph

The Examiner rejected claim 49 under 35 U.S.C. § 112, second paragraph, as allegedly "failing to particularly point out and distinctly claim the subject matter which applicant regards